0001439222-23-000047.txt : 20230303 0001439222-23-000047.hdr.sgml : 20230303 20230303160537 ACCESSION NUMBER: 0001439222-23-000047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230301 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gheuens Sarah CENTRAL INDEX KEY: 0001881190 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 23703805 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wf-form4_167787751050589.xml FORM 4 X0306 4 2023-03-01 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001881190 Gheuens Sarah 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common stock 2023-03-01 4 M 0 3833 0 A 21250 D Common stock 2023-03-03 4 F 0 1134 25.02 D 20116 D Restricted stock units 2023-03-01 4 A 0 12000 0 A Common stock 12000.0 12000 D Stock options (right to buy) 25.01 2023-03-01 4 A 0 44000 0 A 2033-03-01 Common stock 44000.0 44000 D Restricted stock units 2023-03-01 4 M 0 3833 0 D Common stock 3833.0 7667 D Includes 408 shares purchased through the Company's employee stock purchase plan. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2023-03-03